MAPT and Alzheimer disease: Moreover, blood biomarkers such as plasma total tau (t-tau) have shown promising potential to identify neurodegenerations, whereas plasma Aβ42 was shown to be a high-performance biomarker for AD (Dage et al., 2016; Ovod et al., 2017; Nakamura et al., 2018).